within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AX12_Viltolarsen;

model Viltolarsen
  extends Pharmacolibrary.Drugs.ATC.M.M09AX12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M09AX12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Viltolarsen is an antisense oligonucleotide drug designed to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation amenable to exon 53 skipping. It is administered intravenously and was approved by the FDA in August 2020 for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in ambulatory pediatric male patients (ages 4 to <10 years) with Duchenne muscular dystrophy after single and multiple intravenous infusions.</p><h4>References</h4><ol><li><p>Komaki, H, Takeshima, Y, Matsumura, T, Ozasa, S, Funato, M, Takeshita, E, Iwata, Y, Yajima, H, Egawa, Y, Toramoto, T, Tajima, M, &amp; Takeda, S (2020). Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study. <i>Annals of clinical and translational neurology</i> 7(12) 2393â€“2408. DOI:<a href=\"https://doi.org/10.1002/acn3.51235\">10.1002/acn3.51235</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33285037/\">https://pubmed.ncbi.nlm.nih.gov/33285037</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Viltolarsen;
